Tilray Brands, Inc. (TLRY) Earnings Call Transcripts

37 earnings calls from January 2020 to July 28, 2026

NasdaqGS US Health Care Pharmaceuticals

Tilray Brands, Inc.'s Latest Earnings Call - Q3 FY2026

Tilray Brands, Inc. reported its Q3 FY2026 results with net revenue reaching $207 million, marking an 11% organic growth YoY. The company highlighted a record quarter driven by international expansion and the strategic acquisition of BrewDog, positioning Tilray as a $1.2 billion global revenue company. Gross profit increased to $55 million, up 6% from the prior year. Management reaffirmed their adjusted EBITDA guidance of $62 million to $72 million for fiscal 2026, signaling confidence in continued growth.

Reported metrics

MetricValueContext
Net Revenue $206.7 million (beat) 11% increase YoY
Gross Profit $55 million (inline) up 6% YoY
Adjusted EBITDA $10.7 million (beat) 19% increase YoY
Net Loss $25.2 million (inline) improvement from $793.5 million loss YoY
International Cannabis Sales $24.1 million (beat) 73% YoY growth

Guidance from management

Management reaffirmed their fiscal 2026 adjusted EBITDA guidance of $62 million to $72 million, indicating confidence in their strategic direction and operational execution.

What management said

Yes. I mean you answered most of it, but just specifically on the hedge for aluminum, we're currently hedging 65% to 75% of our buy on a month-to-month basis, and we're hedging a year out.
— Carl Merton, Q3 FY2026 earnings call
Just to supplement that a little, when Irwin talked about the acquisitions, it's more about the timing of the acquisitions because we bought those brands after the initial discussions on spring resets that already happened.
— Carl Merton, Q3 FY2026 earnings call

What analysts pressed on

Analysts expressed concerns about the balance between supporting international growth and stabilizing the Canadian market. Questions were also raised about the impact of rising aluminum costs on the beverage segment and the potential regulatory changes affecting hemp-derived THC products.

Main topics on the call

Read the full Tilray Brands, Inc. transcript (Q3 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

About Tilray Brands, Inc.

Tilray Brands, Inc. (TLRY) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 37 calls on record spanning January 14, 2020 to July 28, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.

Earnings Call History

EarningsCalls.dev has 37 Tilray Brands, Inc. earnings call transcripts on record, spanning January 14, 2020 to July 28, 2026. Based on this history, Tilray Brands, Inc. reports quarterly. The most recent call on file is dated July 28, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker
TLRY
Exchange
NasdaqGS
Country
US
Sector
Health Care
Industry
Pharmaceuticals
Calls on record
37
First call
January 14, 2020
Most recent
July 28, 2026
Reporting cadence
quarterly
Quarter Date
Q4 FY2026 Jul 28, 2026 Read transcript
Q3 FY2026 Apr 1, 2026 Read transcript
M&A Calls Mar 2, 2026 Read transcript
Q2 FY2026 Jan 8, 2026 Read transcript
Q1 FY2026 Oct 9, 2025 Read transcript
Q4 FY2025 Jul 28, 2025 Read transcript
Company Conference Presentations Jun 3, 2025 Read transcript
Q3 FY2025 Apr 8, 2025 Read transcript
Q2 FY2025 Jan 10, 2025 Read transcript
Q1 FY2025 Oct 10, 2024 Read transcript
Q4 FY2024 Jul 29, 2024 Read transcript
Q3 FY2024 Apr 9, 2024 Read transcript
Q2 FY2024 Jan 9, 2024 Read transcript
Q1 FY2024 Oct 4, 2023 Read transcript
Special Calls Aug 7, 2023 Read transcript
Q4 FY2023 Jul 26, 2023 Read transcript
Q3 FY2023 Apr 10, 2023 Read transcript
Q2 FY2023 Jan 9, 2023 Read transcript
Q1 FY2023 Oct 7, 2022 Read transcript
Q4 FY2022 Jul 28, 2022 Read transcript
Q3 FY2022 Apr 6, 2022 Read transcript
M&A Calls Mar 3, 2022 Read transcript
Q2 FY2022 Jan 10, 2022 Read transcript
Q1 FY2022 Oct 7, 2021 Read transcript
Shareholder/Analyst Calls Sep 10, 2021 Read transcript
Company Conference Presentations Sep 10, 2021 Read transcript
Special Calls Aug 17, 2021 Read transcript
Q4 FY2021 Jul 28, 2021 Read transcript
Shareholder/Analyst Calls Apr 14, 2021 Read transcript
Q3 FY2021 Apr 12, 2021 Read transcript
Q2 FY2021 Jan 14, 2021 Read transcript
M&A Calls Dec 16, 2020 Read transcript
Shareholder/Analyst Calls Nov 17, 2020 Read transcript
Q1 FY2021 Oct 15, 2020 Read transcript
Q4 FY2020 Jul 29, 2020 Read transcript
Q3 FY2020 Apr 15, 2020 Read transcript
Q2 FY2020 Jan 14, 2020 Read transcript